QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
Business Wire•06/10/2026•16:05 ET
0
Key Highlights
- ➤QIAGEN launched IPA Investigator for natural-language biological data analysis
- ➤QIAGEN introduced Discovery Platform for AI-powered drug discovery workflows
- ➤QIAGEN Digital Insights tools are used by around 150,000 users
- ➤QIAGEN serves more than 500,000 customers worldwide
- ➤AI bioinformatics market projected to exceed $25 billion by 2031
Expert Statements
Dominic John, Vice President and Head of QIAGEN Digital Insights
“AI can deliver an answer in seconds, but in science, speed without evidence can create false confidence”
Dominic John, Vice President and Head of QIAGEN Digital Insights
“Our approach is to combine the speed of AI with expert-curated biomedical knowledge and traceable scientific evidence so researchers can examine the evidence behind the results and evaluate them for themselves.”
Simona Chera, Professor at the University of Bergen
“We deliberately introduced misleading comparisons to see how IPA Investigator would respond. It identified the problem, cautioned us against overinterpreting the results and suggested a better experimental design.”
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
* New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results
Get started
Create a free account to read the full story.